Abstract
Hypersensitivity pneumonitis (HP) is characterized as an immune-mediated interstitial lung disease with heterogeneous clinical manifestations and presents complex diagnostic challenges. This clinical guideline provides a comprehensive framework for diagnosing and managing HP, accentuating the evolving classification into fibrotic and nonfibrotic subtypes. By integrating current clinical guidelines and expert consensus, it addresses essential aspects such as radiologic and histopathologic findings, diagnostic strategies, and pharmacologic management. Tailored to the healthcare context in Korea, this guideline presents clinicians with a structured approach to diagnose and manage HP, considering regional variations in antigen exposure and clinical presentation. The recommendations are based on both international and local data, aiming to enhance outcomes for Korean patients through timely and accurate diagnosis, individualized treatment plans, and meticulous monitoring.